Long acting GLP-1 receptor agonist (injectable)
Dulaglutide 1.5 mg subcutaneous once weekly
DULA_SC_1p5MG_QW
Related
- All doses pooled: Dulaglutide injection
- Dulaglutide 1.0 mg injection once weekly
- Dulaglutide 3.0 mg subcutaneous once weekly
- Dulaglutide 4.5 mg subcutaneous once weekly
- Dulaglutide 0.25 mg injection once weekly
- Dulaglutide 0.5 mg injection once weekly
- Dulaglutide 0.75 mg subcutaneous once weekly
- Dulaglutide flexible dose injection once weekly
- Dulaglutide 2.0 mg injection once weekly
- Dulaglutide 0.1 mg injection once weekly
- Dulaglutide 0.75 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.08 (-1.27 to -0.89) | 0.64 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.15 (-1.44 to -0.85) | 0.76 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.09 (-0.35 to 0.54) | 0.45 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.13 (-1.52 to -0.61) | 0.45 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.73 (-2.33 to -0.52) | 0.84 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.78 (-1.10 to -0.43) | 0.54 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Dulaglutide 0.75 mg subcutaneous once weekly | MD -0.07 (-0.46 to 0.29) | 0.80 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Dulaglutide 0.75 mg subcutaneous once weekly | MD -0.03 (-0.40 to 0.33) | 0.74 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.76 (-1.37 to -0.08) | 0.44 |
| Type 2 diabetes (adults) | HbA1c change | weeks 64 to 130 (target week 104) | Insulin glargine | MD -0.31 (-1.28 to 0.70) | 0.75 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.37 (-1.96 to -0.77) | 0.45 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -0.14 (-2.45 to 2.80) | 0.36 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.99 (-2.22 to 0.24) | 0.60 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.20 (-4.74 to 2.65) | 0.36 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.18 (-2.25 to -0.09) | 0.33 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.38 (-7.21 to 2.72) | 0.60 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Dulaglutide 0.75 mg subcutaneous once weekly | MD -0.77 (-5.39 to 3.81) | 0.61 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.32 (-2.42 to 1.63) | 0.54 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 64 to 130 (target week 104) | Insulin glargine | MD -3.21 (-7.89 to 1.90) | 0.61 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 8.05 (2.27 to 18.86) | 0.60 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Semaglutide 1.0 mg subcutaneous once weekly | OR 0.56 (0.20 to 1.78) | 0.48 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 4.86 (0.65 to 19.63) | 0.72 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 9.20 (3.52 to 19.81) | 0.82 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.20 (0.05 to 0.60) | 0.63 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.87 (0.99 to 3.60) | 0.57 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.18 (0.66 to 1.89) | 0.58 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.58 (0.22 to 1.39) | 0.65 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.45 (-3.53 to -1.37) | 0.54 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 3.97 (-0.91 to 8.97) | 0.41 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -2.63 (-8.82 to 3.52) | 0.50 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -1.82 (-5.64 to 2.05) | 0.36 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 64 to 130 (target week 104) | Insulin glargine | MD -1.32 (-12.94 to 10.22) | 0.59 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 5.89 (1.32 to 26.80) | 0.60 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 1.62 (0.25 to 5.80) | 0.23 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 2.90 (0.53 to 15.42) | 0.44 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Semaglutide 1.0 mg subcutaneous once weekly | OR 0.24 (0.10 to 0.77) | 0.30 |
| Type 2 diabetes (adults) | All cause mortality | longest follow-up | Placebo | HR 0.90 (0.60 to 1.37) | 0.46 |
| Type 2 diabetes (adults) | Three point MACE | longest follow-up | Placebo | HR 0.88 (0.51 to 1.55) | 0.51 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.68 (-1.21 to 2.76) | 0.45 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.90 (0.76 to 1.04) | 0.55 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.48 (1.03 to 2.14) | 0.53 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.09 (2.56 to 3.74) | 0.45 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.52 (1.99 to 3.19) | 0.53 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.77 (1.49 to 2.12) | 0.45 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.89 (1.48 to 2.45) | 0.45 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 1.53 (0.19 to 10.98) | 0.53 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 1.01 (0.36 to 2.17) | 0.43 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 1.24 (0.51 to 2.66) | 0.48 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 1.36 (0.45 to 3.47) | 0.34 |
| Type 2 diabetes (adults) | Any cancer | longest follow-up | Placebo | HR 1.01 (0.32 to 3.22) | 0.56 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.69 (0.04 to 10.80) | 0.49 |
| Children and adolescents with type 2 diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.36 (0.03 to 3.14) | 0.75 |
| Children and adolescents with type 2 diabetes | Nausea | longest follow-up | Placebo | HR 1.91 (0.45 to 8.36) | 0.38 |
| Children and adolescents with type 2 diabetes | Vomiting | longest follow-up | Placebo | HR 2.90 (0.49 to 16.87) | 0.49 |
| Children and adolescents with type 2 diabetes | Diarrhea | longest follow-up | Placebo | HR 1.55 (0.41 to 5.73) | 0.40 |
| Polycystic ovary syndrome | Nausea | longest follow-up | Standard care or no added treatment | HR 17.26 (1.78 to 401) | 0.02 |
| Polycystic ovary syndrome | Diarrhea | longest follow-up | Standard care or no added treatment | HR 0.52 (0.01 to 39.60) | 0.60 |
Trials
- NCT05407961A Phase 1b, 2-Part, Investigator- and Participant-Blind, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3532226 in Participants With Type 2 Diabetes Mellitus2022 · 72 randomized · 12 weeks
- NCT04867785A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes2021 · 281 randomized · 36 weeks
- NCT04965506A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes2021 · 252 randomized · 20 weeks
- NCT05048719A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus2021 · 383 randomized · 26 weeks
- NCT04876027Dulaglutide and Calorie Restrict Diet (CRD) in Overweight/Obese Patients With Polycystic Ovary Syndrome2021 · 68 randomized · 26.07 weeks
- NCT04466904A Multiple Dose Human Tolerability and Pharmacokinetic Study of IBI362 in Chinese Patients With Type 2 Diabetes Mellitus and Poor Glycemic Control2020 · 43 randomized · 12 weeks
- S0030502020 · 60 randomized · 12 weeks
- S0028852019 · 25 randomized · 12 weeks
- AWARD-11A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus2018 · 1,842 randomized · 52 weeks
- D-LIFTEffect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial2018 · 64 randomized · 24 weeks
- NCT03131687A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus2017 · 318 randomized · 26 weeks
- NCT03824002Arterial Stiffness and Endothelial Function Indexes, Relationships With Clinical and Laboratory Variables in a Group of Diabetic Patients in Treatment With Dulaglutide: a Case-control Study2017 · 39.11 weeks
- SUSTAIN 7Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes2016 · 1,201 randomized · 40 weeks
- AWARD-PEDSA Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)2016 · 154 randomized · 26 weeks
- AWARD-10A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus2015 · 424 randomized · 24 weeks
- AWARD-9A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine2014 · 300 randomized · 28 weeks
- AWARD-8A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)2013 · 300 randomized · 24 weeks
- AWARD-CHN1The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus2012 · 737 randomized · 26 weeks
- AWARD-7A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease2012 · 577 randomized · 52 weeks
- AWARD-CHN2The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea2012 · 774 randomized · 52 weeks
- AWARD-6A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide With Once-Daily Liraglutide in Patients With Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)2012 · 599 randomized · 26 weeks
- REWINDThe Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)2011 · 9,901 randomized
- NCT01126580The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)2010 · 807 randomized · 52 weeks
- AWARD-1A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)2010 · 978 randomized · 52 weeks
- NCT01191268The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)2010 · 884 randomized · 52 weeks
- AWARD-2A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride2010 · 810 randomized · 78 weeks
- NCT01149421The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus2010 · 755 randomized · 26 weeks
- NCT00791479Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions2008 · 167 randomized · 12 weeks